Mesenchymal Stem Cells as Regulators of Carcinogenesis

Hayal, Taha Bartu; Kıratlı, Binnur; Şişli, Hatice Burcu; Şahın, Fikrettin; Doğan, Ayşegül

doi:10.1007/5584_2018_311

Cited by 11 publications

(6 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this dual nature of MSCs is not unique to fibrosis. Published studies suggest that MSCs also present dual roles in cancer progress [ 266 ] and in inflammatory cascade [ 267 ]. In both cases, the microenvironment that MSCs face plays major contribution in switching their cellular behaviors and finally outcomes in disease development.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin

Qin

Liu

Bao³

et al. 2022

Acta Pharmacol Sin

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin

Qin

Liu

Bao³

et al. 2022

Acta Pharmacol Sin

View full text Add to dashboard Cite

“…In an early study in which mouse cancer models were used, the immune cells including neutrophils, macrophages and mast cells, were found to express MMP-9, contributing to the occurrence of skin squamous cell carcinogenesis [ 117 ]. Furthermore, MSCs were reported to be regulated by a variety of cytokines and chemokines in tumour tissues, mediating cell proliferation, angiogenesis, and metastasis [ 118 ]. Evidence suggests that MSCs can inhibit the growth of tumour cells in a healthy microenvironment and that only after acquiring tumour-like gene mutations can secrete factors to promote tumour progression [ 119 ].…”

Section: Current Challenges and Safety Issuesmentioning

confidence: 99%

The therapeutic potential of mesenchymal stem cells in treating osteoporosis

et al. 2021

View full text Add to dashboard Cite

Osteoporosis (OP), a common systemic metabolic bone disease, is characterized by low bone mass, increasing bone fragility and a high risk of fracture. At present, the clinical treatment of OP mainly involves anti-bone resorption drugs and anabolic agents for bone, but their long-term use can cause serious side effects. The development of stem cell therapy and regenerative medicine has provided a new approach to the clinical treatment of various diseases, even with a hope for cure. Recently, the therapeutic advantages of the therapy have been shown for a variety of orthopedic diseases. However, these stem cell-based researches are currently limited to animal models; the uncertainty regarding the post-transplantation fate of stem cells and their safety in recipients has largely restricted the development of human clinical trials. Nevertheless, the feasibility of mesenchymal stem cells to treat osteoporotic mice has drawn a growing amount of intriguing attention from clinicians to its potential of applying the stem cell-based therapy as a new therapeutic approach to OP in the future clinic. In the current review, therefore, we explored the potential use of mesenchymal stem cells in human OP treatment.

show abstract

“…Due to their tumor tropism and immunosuppressive properties, MSCs have been proved to exhibit diverse biological functions in tumor ( 20 ). Numerous studies have provided the evidence that tumor-derived MSCs could promote the growth and metastasis of a variety of malignances, via the secretion of trophic factors or cell-to-cell contact with the other TME cells ( 21 , 22 ). MSCs emerging in these studies were obtained from tumor tissues by the method of enzymatic digestion and identified based on the morphological, phenotypic, and differentiated parameters of the isolated cells.…”

Section: The Pro- and Antitumor Properties Of Mscsmentioning

confidence: 99%

Crosstalk Between Mesenchymal Stromal Cells and Tumor-Associated Macrophages in Gastric Cancer

Zheng

2020

Front. Oncol.

View full text Add to dashboard Cite

Tumor microenvironment (TME) consisting of distinct cell types including stromal cells and immune cells has recently emerged as a pivotal player in tumor development and progression. Mesenchymal stromal cells (MSCs) and tumor-associated macrophages (TAMs) are two representative cells in the TME with plastic properties. This review will focus on the evolution of phenotypes and functions of either MSCs or TAMs, which is “educated” by the TME, as well as interactions between MSCs and TAMs contributing to the distinct stages of tumor biology in gastric cancer. MSCs exert immunoregulatory effects on macrophages and polarize them toward M2-like TAMs, via cell–cell contact and paracrine or extracellular vesicle (EV) transfer mechanism. In turn, M2-TAMs modulate the transition of “naive” MSCs into tumor-derived MSCs, which possess a more potent pro-tumor role than the parent. Moreover, the cross talk between MSCs and TAMs could contribute to cancer biology by inducing the EMT process, metastasis, immune invasion, and immunotherapy resistance in cancer cells. However, molecular mechanisms underlying interactions between MSCs and TAMs in gastric cancer progression need to be thoroughly elucidated, which may provide attractive targets for making promising novel strategies for gastric cancer therapy.

show abstract

Mesenchymal Stem Cells as Regulators of Carcinogenesis

Cited by 11 publications

References 143 publications

Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin

Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin

The therapeutic potential of mesenchymal stem cells in treating osteoporosis

Crosstalk Between Mesenchymal Stromal Cells and Tumor-Associated Macrophages in Gastric Cancer

Contact Info

Product

Resources

About